Anebulo Pharmaceuticals (ANEB) AI Stock Analysis

• Market Cap: $17.60M
• Dividend Yield: N/A
• Average Volume (3M): 16.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: N/A
• EPS Growth: 23.10%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 40,784,733
• 10 Day Avg. Volume: 7,376
• 30 Day Avg. Volume: 16,982
• PEG Ratio: 0.26
• Price to Book (P/B): 4.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.67
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.04
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.45 ▼(-59.91% Downside)
• Action: Reiterated Date: 02/14/26
• Date: Action: Reiterated 02/14/26

The score is pressured primarily by weak financial performance (pre-revenue, ongoing losses and cash burn) and very bearish technicals (price far below major moving averages with negative MACD). Corporate events add significant risk due to the planned Nasdaq delisting and deregistration, while valuation provides limited support given the negative P/E and no dividend.

Positive Factors

Zero debt and positive equity

Anebulo's zero-debt capital structure materially reduces refinancing and interest-rate risk, preserving financial flexibility for a clinical-stage biotech. Positive equity provides a solvency buffer that extends runway vs highly levered peers, supporting continued R&D investment while external financing is arranged.

Clear strategic focus on lead selonabant program

Management's explicit redeployment of resources toward the lead selonabant program signals prioritization of development capital and operational focus. Concentrating R&D spend on the most promising asset can accelerate trials and value creation while reducing administrative distraction from broader non-core activities.

Trend toward reduced cash burn vs prior years

Free cash flow has shown improvement versus larger outflows in FY2023 and FY2024, indicating management has implemented cost controls or efficiency measures. This trend, if sustained, lowers near-term financing pressure and improves odds of funding clinical milestones without immediate large capital raises.

Negative Factors

Pre-revenue clinical-stage profile

Anebulo's lack of revenue is a persistent structural constraint: value depends entirely on clinical success and milestone timing. Without commercial cash flow, the firm cannot rely on operating leverage, making its viability contingent on successful trials, partnerships, or external financing over the medium term.

Persistent negative free cash flow

Consistent negative operating and free cash flow requires ongoing external financing, increasing dilution or debt risk. Although FCF broadly tracks net loss (cash-based burn), FY2025 worsened to roughly -$6.35M, underscoring a structural funding need that could pressure capitalization absent milestone-driven inflows.

Planned Nasdaq delisting and deregistration

Voluntary delisting and SEC deregistration materially reduce liquidity, transparency and access to public capital markets. Over the medium term this impairs the company's ability to attract institutional investors, raises financing friction, and may increase the cost or limit options for raising required development capital.

Anebulo Pharmaceuticals Business Overview & Revenue Model

Company Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

How the Company Makes Money

Anebulo Pharmaceuticals generates revenue primarily through the development and potential commercialization of its lead product candidate, ANEB-001. As a clinical-stage company, Anebulo's current revenue streams are limited, and it largely relies on funding through public and private investment to support its research and development activities. In the future, the company plans to earn income through licensing agreements, strategic partnerships, and sales of its pharmaceutical products upon receiving regulatory approval. Significant partnerships with larger pharmaceutical companies could also contribute to its revenue by providing milestone payments, royalties, and collaborative research funding.

Anebulo Pharmaceuticals Financial Statement Overview

Summary

Pre-revenue profile with persistent losses (TTM net loss ~-$8.0M) and ongoing negative free cash flow (TTM FCF ~-$5.8M). Balance sheet is a relative strength with zero debt and positive equity (~$7.9M), but continued burn implies ongoing funding/dilution risk.

Income Statement

The company continues to generate no revenue (TTM (Trailing-Twelve-Months) and prior annual periods), which is typical for an early-stage biotech but limits visibility into operating leverage. Losses remain persistent: TTM (Trailing-Twelve-Months) net loss is about $8.0M, broadly in line with recent years (around $8.5M in FY2025 and $8.2M in FY2024), but still meaningfully negative. The key strength is that losses have improved versus the much larger FY2023 loss (~$11.7M), yet the overall profitability profile remains weak with no clear inflection from commercialization.

Balance Sheet

Balance sheet risk looks relatively contained due to zero debt across periods, which reduces refinancing and interest-rate risk. Equity remains positive (about $7.9M in TTM (Trailing-Twelve-Months)), supporting solvency. The main weakness is ongoing losses driving poor returns on equity (TTM (Trailing-Twelve-Months) return on equity around -0.75), and equity has declined from FY2022 levels, signaling continued dilution/burn risk if spending persists without revenue.

Cash Flow

Cash generation is weak: operating cash flow and free cash flow are negative in every period, with TTM (Trailing-Twelve-Months) free cash flow around -$5.8M. There is some improvement versus FY2024 (-$8.1M) and FY2023 (-$9.7M), but FY2025 free cash flow worsened again to roughly -$6.35M, pointing to volatility in burn. A positive is that free cash flow broadly tracks net loss (similar magnitude), suggesting losses are largely cash-based rather than being masked by major non-cash items—however, the business still consumes cash with no revenue offset.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-8.32M	-8.10M	-7.79M	-11.73M	-6.83M	-30.24M
Net Income	-7.98M	-8.48M	-8.20M	-11.73M	-6.83M	-30.25M
Balance Sheet
Total Assets	9.42M	12.15M	4.07M	11.67M	15.58M	21.65M
Cash, Cash Equivalents and Short-Term Investments	9.04M	11.63M	3.09M	11.25M	14.55M	19.99M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.49M	487.69K	260.58K	1.07M	512.53K	241.63K
Stockholders Equity	7.94M	11.66M	3.81M	10.60M	15.07M	21.41M
Cash Flow
Free Cash Flow	-5.84M	-6.35M	-8.09M	-9.68M	-5.44M	-4.87M
Operating Cash Flow	-5.84M	-6.35M	-8.09M	-9.68M	-5.44M	-4.87M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	-116.66K	14.88M	-62.35K	6.38M	0.00	21.83M

Anebulo Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANEB, the sentiment is Negative. The current price of 1.13 is above the 20-day moving average (MA) of 0.68, above the 50-day MA of 1.13, and below the 200-day MA of 1.86, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 20.79 is Positive, neither overbought nor oversold. The STOCH value of 25.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANEB.

Anebulo Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CNTX	57 Neutral	$227.86M	-8.86	-33.68%	―	―	69.30%
ANRO	56 Neutral	$600.20M	-8.40	-45.01%	―	―	-7.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRZN	50 Neutral	$231.43M	-1.24	―	―	-63.96%	-28.50%
VTGN	44 Neutral	$22.08M	-0.35	―	―	-33.00%	54.91%
BYSI	43 Neutral	$55.93M	―	―	―	―	―
ANEB	41 Neutral	$17.60M	-2.22	-145.11%	―	―	23.10%

Anebulo Pharmaceuticals Corporate Events

Anebulo Pharmaceuticals Announces Voluntary Nasdaq Delisting Plan

On February 5, 2026, Anebulo Pharmaceuticals’ board approved the voluntary delisting of the company’s common stock from the Nasdaq Capital Market and the subsequent deregistration of its shares with the U.S. Securities and Exchange Commission, a move publicly announced in a press release dated February 6, 2026. While the company remains in compliance with Nasdaq listing standards, the board concluded that the costs and administrative burdens of being a publicly listed, SEC-reporting company outweigh the benefits, especially as it focuses resources on advancing its lead selonabant program. The delisting is expected to become effective on February 27, 2026, after the planned filing of Form 25, with a Form 15 to be filed around the same date to terminate SEC registration and suspend periodic reporting obligations, after which trading in Anebulo’s shares would be limited to private transactions and potentially over-the-counter markets, altering liquidity and transparency for existing shareholders.

The most recent analyst rating on (ANEB) stock is a Sell with a $0.91 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.

Anebulo Pharmaceuticals Completes Oversubscribed Share Repurchase Tender

On January 29, 2026, Anebulo Pharmaceuticals reported the final results of its voluntary self-tender offer, which expired on January 26, 2026, to repurchase up to 300,000 shares of common stock at $3.50 per share. The offer was heavily oversubscribed, with 4,907,881 shares validly tendered and not withdrawn; Anebulo ultimately bought the full 300,000-share maximum, including 134,306 odd-lot shares accepted in full, at an aggregate cost of about $1.05 million, representing approximately 0.73% of shares outstanding as of January 26, 2026. The shares, other than odd lots, were accepted on a pro rata basis using a final proration factor of 3.47392%, and payment in cash without interest will be made promptly to participating shareholders. Management said the transaction met its goal of offering smaller shareholders a chance to exit at a significant premium to market while modestly shrinking the shareholder base, a move that could streamline the company’s investor roster without materially affecting its capital structure.

The most recent analyst rating on (ANEB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.

Anebulo Pharmaceuticals Announces Oversubscribed Self-Tender Offer Results

On January 27, 2026, Anebulo Pharmaceuticals reported preliminary results from its voluntary self-tender offer for up to 300,000 shares of its common stock at $3.50 per share in cash, following the offer’s expiration on January 26, 2026. The offer was significantly oversubscribed, with about 4.9 million shares properly tendered, leading the company to expect pro rata acceptance of approximately 300,000 shares—about 0.73% of shares outstanding as of January 26—at an estimated aggregate cost of $1.05 million, excluding fees and expenses. A preliminary proration factor of roughly 3.5% is expected, with “odd lot” tenders to be accepted in full; final share counts and proration will be confirmed after the guaranteed delivery period, and accepted shares will be paid for in cash while unpurchased shares will be returned promptly. The oversubscription suggests robust shareholder interest in the liquidity event and will result in a modest reduction in Anebulo’s share count, with limited but targeted impact on capital allocation and ownership structure.

The most recent analyst rating on (ANEB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.

Anebulo Pharmaceuticals Launches Self-Tender Offer to Go Private

On December 22, 2025, Anebulo Pharmaceuticals announced that its board had abandoned a previously proposed large reverse stock split and related special shareholder meeting in favor of launching a voluntary self-tender offer as part of its plan to go private. The company intends to commence a cash tender offer to buy up to 300,000 shares of its common stock at $3.50 per share, for a total of up to $1.05 million, a move aimed at keeping its shareholder count below 300, the threshold needed to complete its going-private transaction. The board concluded that the reverse split had become too costly after certain investors distributed holdings across multiple small accounts to maximize fractional share payouts, significantly increasing the projected expense of that strategy. By shifting to the self-tender approach, Anebulo is seeking a more economically efficient path to delisting and deregistration while retaining the option to revisit a reverse split or other structural transaction in the future if conditions change.

The most recent analyst rating on (ANEB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.